SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug ‘SNB-101’ on Pancreatic Cancer

SN Bioscience Co. Ltd. announced that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.